23.3 C
New York
Thursday, September 23, 2021

Here are all the latest developments about Chembio Diagnostics Inc (CEMI) stock

Chembio Diagnostics Inc. (CEMI) shares gained 0.28% to close Thursday’s session at $3.52. CEMI shares have fallen by -50.84% over the last 12 months, and they have moved down by -6.88% in the past week. The company has a current market of $70.79 million and its outstanding shares stood at 20.16 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Launching diagnostic tool to differentiate between flu and COVID-19

On April 01, 2021, Chembio Diagnostics, Inc. announced the commercial launch of a rapid point-of-care COVID-19/Flu A&B test which his approved by the FDA. The new test is immediately available for shipment to customers across the United States.

The rapid immunoassay testsimultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab and provide the results in 15 minutes.

Recent financial results

On March 12, 2021,CEMI announced financial results for the quarter and year ended December 31, 2020.

Fourth Quarter 2020 financial highlights

  • For the fourth quarter of 2020, the total revenue was $10.2 million
  • CEMI Net product saleswere $6.9 million for Q4 2020.
  • For the fourth quarter of 2020, the gross product margin was $492,000, compared to $1.2 million for the prior-year period.
  • CEMI spent $1.2 million in research and development expenses in the reported quarter.
  • Selling, general and administrative expenses were $3.5 million, for the fourth quarter of 2020.
  • CEMI suffered a net loss of $7.1 million, or $0.35 per diluted share in the fourth quarter of 2020, compared to a net loss of $3.9 million, or $0.23 per diluted share, for the prior-year period.

The full Year 2020 financial highlights

  • CEMI reported revenue of $32.5 millionfor 2020.
  • Net product sales for the full year 2020 were $24.8 million
  • For the reported year, the gross product margin was $0.9 million, compared to $6.5 million for the prior year 2019.
  • Research and development expenses increased by $0.9 million, or 11%, in 2020 compared to 2019.
  • In 2020, Selling, general and administrative expenses increased by $4.9 million, or 30%, compared to 2019.
  • CEMI suffered a net loss of $25.5 millionor $1.34 per diluted share for 2020 compared to a net loss of $13.7 million, or $0.81 per diluted share in 2019.
  • As of December 31, 2020, CEMI had cash and cash equivalents of $23.1 million.

New members to the CEMI Board of directors

On March 8, 2021, CEMI announced the appointment of David Bespalko to the Company’s Board of Directors.

MrBespalkohas 35 years of leadership experience in the global Vitro diagnostics market.

On December 17, 2020, CEMI announced the appointment of David Acheson, M.D. to the Company’s Board of Directors.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.